Osteopontin: A potentially important therapeutic target in cancer Journal Article
| Authors: | Ahmed, M.; Behera, R.; Chakraborty, G.; Jain, S.; Kumar, V.; Sharma, P.; Bulbule, A.; Kale, S.; Kumar, S.; Mishra, R.; Raja, R.; Saraswati, S.; Kaur, R.; Soundararajan, G.; Kumar, D.; Thorat, D.; Sanyal, M.; Ramdasi, A.; Ghosh, P.; Kundu, G. C. |
| Article Title: | Osteopontin: A potentially important therapeutic target in cancer |
| Abstract: | Introduction: Cancer is an extremely complex disease and most cancer treatments are limited to chemotherapy, radiation and surgery. The progression of tumours towards malignancy requires the interaction of various cytokines, growth factors, transcription factors and effector molecules. Osteopontin is a cytokine-like, calcium-binding, extracelular-matrix- associated member of the small integrin-binding ligand, N-linked glycoprotein (SIBLING) family of proteins. It plays an important role in determining the oncogenic potential of various cancers. The role of osteopontin in various pathophysiological conditions suggests that the alteration in post-translational modification result in different functional forms that might change its normal physiological functions. Areas covered: Osteopontin -based anticancer therapy, which may provide a new insight for the effective management of cancer. Expert opinion: A better understanding of the signalling mechanism by which osteopontin promotes tumourigenesis may be useful in crafting novel osteopontin -based anticancer therapy. The role of osteopontin in promoting cancer progression is the subject of in depth investigation and thus targeting osteopontin might be a suitable therapeutic approach for the treatment of cancer. © 2011 Informa UK, Ltd. |
| Keywords: | signal transduction; cancer chemotherapy; unclassified drug; review; cancer growth; drug efficacy; nonhuman; antineoplastic agents; antineoplastic agent; protein function; neoplasms; animals; metastasis; microrna; protein targeting; small interfering rna; antineoplastic activity; drug design; angiogenesis; carcinogenesis; monoclonal antibody; drug delivery systems; lung metastasis; protein processing; protein processing, post-translational; disease progression; celecoxib; stroma; targeted therapy; cyclopamine; protein structure; hermes antigen; simvastatin; short hairpin rna; integrin; arginylglycylaspartic acid; 2 morpholino 8 phenylchromone; trichostatin a; complementary rna; aptamer; protein antibody; lymphocyte antibody; vitronectin receptor; osteopontin; prognostic marker; tumour-stroma interaction; agelastatin a; cd44 antibody; echistatin; etaracizumab; integrin alpha9beta1; monoclonal antibody vitronectin receptor; n acetylprolylhistidylserylcysteinylasparagine amide; osteopontin antibody; parecoxib; triterpene lupeol; very late activation antigen 4 |
| Journal Title: | Expert Opinion on Therapeutic Targets |
| Volume: | 15 |
| Issue: | 9 |
| ISSN: | 1472-8222 |
| Publisher: | Informa Healthcare |
| Date Published: | 2011-09-01 |
| Start Page: | 1113 |
| End Page: | 1126 |
| Language: | English |
| DOI: | 10.1517/14728222.2011.594438 |
| PROVIDER: | scopus |
| PUBMED: | 21718227 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 3 October 2011" - "CODEN: EOTTA" - "Source: Scopus" |
